Inflammatory Bowel Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation.
Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases.
Microbes with higher metabolic independence are enriched in human gut microbiomes under stress.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases.
Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies.
Revolutionizing immune research with organoid-based co-culture and chip systems.
A Comprehensive Review of the Triangular Relationship among Diet-Gut Microbiota-Inflammation.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q3 2027.
Clinical MilestonesViewHide
- 2026-06-25Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life DataResults expected Q4 2027
- 2026-03-13Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel DiseaseResults expected Q3 2027
- 2026-08-31Longterm Transfer of FRozen Encapsulated Multidonor Stool Filtrate or Encapsulated Multidonor Microbiome for Chronic Active Ulcerative COlitisPrimary completion
- 2026-05-01Subcutaneous Infliximab After A Previous Intravenous Dose OptimizationPrimary completion
- 2027-09-01ClinicalImmunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Inflammatory Bowel Disease on Biologic Immunosuppressive TherapiesWithdrawn
- 2026-08-31ClinicalLongterm Transfer of FRozen Encapsulated Multidonor Stool Filtrate or Encapsulated Multidonor Microbiome for Chronic Active Ulcerative COlitisPrimary completion
- 2026-06-25ClinicalDigestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life DataResults expected Q4 2027
- 2026-05-01ClinicalSubcutaneous Infliximab After A Previous Intravenous Dose OptimizationPrimary completion
- 2026-03-13ClinicalActivation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel DiseaseResults expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Jayempi is indicated in combination with other immunosuppressive agents for the prophylax… (2021)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Inflammatory Bowel Diseases35
- Gastrointestinal Microbiome25
- Microbiota8
- Colitis5
- Colitis, Ulcerative5
- Crohn Disease4
- Diet4
- Homeostasis4
Leading journals6
- Frontiers in immunology8
- International journal of molecular sciences8
- Gut5
- Nature communications4
- Nutrients4
- EBioMedicine3
Leading researchers8
- Liu Y3
- Armuzzi A2
- Bergen SE2
- Butterworth AS2
- Cammarota G2
- Danese S2
- Danesh J2
- Deleu S2
Affiliations (unnormalised)6
- Imperial College London5
- University of Cambridge4
- School of Medicine3
- University Medical Center Groningen3
- Wellcome Sanger Institute3
- Biomedical Center2
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Inflammatory bowel diseases are chronic, non-specific inflammatory disorders of the gastrointestinal tract. The term includes Crohn disease and ulcerative colitis. The literature describes them as heterogeneous conditions involving clinical, immunological, molecular, genetic, and microbial variation.
The etiology is described as multifactorial, with genetic and environmental contributions. Review abstracts also describe a complex interplay between genetic, immunologic, microbial, and environmental factors. Dysbiosis of the gut microbiome is increasingly considered causally related to inflammatory bowel diseases.
The disease is associated with disturbed host-microbe interactions and functional dysbiosis in the gut microbiome. Literature highlights reduced short-chain fatty acid-producing bacteria and reduced fecal short-chain fatty acids in active disease, alongside impaired intestinal homeostasis and barrier function. Reviews also emphasize roles for innate immunity, cytokines, interleukin-23, mucins, and intestinal permeability in the inflammatory process.
Environmental factors are implicated in disease risk, and dysbiosis of the gut microbiome is described as causally related. A Western lifestyle is noted as strongly affecting the microbiome changes associated with inflammatory bowel diseases. Genetic factors are also part of the risk background described in the supplied material.
The supplied grounding supports treatment at the modality level rather than specific regimens. Literature coverage includes therapy and drug therapy, and the co-studied dextran sulfate indicates use in experimental or model contexts rather than standard treatment. The review abstracts also discuss microbiota-directed approaches such as probiotics and manipulation of gut microbiota, but no definitive standard drug-class treatment is specified in the grounding.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.